Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias

被引:17
|
作者
Albers, Max B. [1 ,2 ,3 ]
Almquist, Martin [1 ,2 ]
Bergenfelz, Anders [1 ,2 ]
Nordenstrom, Erik [1 ,2 ]
机构
[1] Lund Univ, Skane Univ Hosp, Dept Surg, Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden
[3] Philipps Univ Marburg, Dept Visceral Thorac & Vasc Surg, Marburg, Germany
关键词
Neuroendocrine neoplasia; Perioperative complications; Surgery; Gastro-entero-pancreatic system; Small intestine; Pancreas; ENETS CONSENSUS GUIDELINES; POSTOPERATIVE COMPLICATIONS; TUMORS; MANAGEMENT; UPDATE; RESECTION; CLASSIFICATION; MORTALITY; PROPOSAL; OUTCOMES;
D O I
10.1007/s00423-020-01869-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose Surgery is recommended for most patients with gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NENs). Rates of complications and perioperative mortality have been reported in few mostly retrospective single-center series, but there has been no detailed analysis on risk factors for perioperative complications and mortality to date. Methods Data of patients with GEP-NENs operated between January 2015 and September 2018 were retrieved from EUROCRINE (c), a European online endocrine surgical quality registry, and analyzed regarding rate and risk factors of surgical complications. Risk factors were assessed by logistic regression. Results Some 376 patients (211 female, 167 male; age median 63, range 15-89 years) were included. Most NENs were located in the small intestine (SI) (n = 132) or pancreas (n = 111), the rest in the stomach (n = 34), duodenum (n = 30), appendix (n = 30), colon, and rectum (n = 22), or with unknown primary (n = 15). Of the tumors, 320 (85.1%) were well or moderately differentiated, and 147 (39.1%) of the patients had distant metastases at the time of operation. Severe complications (Dindo-Clavien >= 3) occurred in 56 (14.9%) patients, and 4 (1.1%) patients died perioperatively. Severe complications were more frequent in surgery for duodenopancreatic NENs (n = 31; 22.0%) compared with SI-NENs (n = 15; 11.4%) (p = 0.014), in patients with lymph node metastases operated with curative aim of surgery (n = 24; 21.4%) versus non-metastasized tumors or palliative surgery (n = 32; 12.1%) (p = 0.020), and in functioning tumors (n = 20; 23.0%) versus non-functioning tumors (n = 30; 13.5%) (p = 0.042). Complication rates were not significantly associated with tumor stage or grade. Conclusions Severe complications are frequent in GEP-NEN surgery. Besides duodenopancreatic tumor location, curative resection of nodal metastases and functioning tumors are risk factors for complications.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
  • [11] Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
    Christian Fottner
    Martina Ferrata
    Matthias M. Weber
    Reviews in Endocrine and Metabolic Disorders, 2017, 18 : 393 - 410
  • [12] Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
    Fottner, Christian
    Ferrata, Martina
    Weber, Matthias M.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2017, 18 (04): : 393 - 410
  • [13] Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract
    Goretzki, Peter E.
    Mogl, Martina T.
    Akca, Aycan
    Pratschke, Johann
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2018, 19 (02): : 169 - 178
  • [14] GEP-NETS UPDATE A review on surgery of gastro-entero-pancreatic neuroendocrine tumors
    Partelli, Stefano
    Maurizi, Angela
    Tamburrino, Domenico
    Baldoni, Andrea
    Polenta, Vanessa
    Crippa, Stefano
    Falconi, Massimo
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 171 (04) : R153 - R162
  • [15] GASTRO-ENTERO-PANCREATIC SYSTEM
    LECOMPTE, PM
    NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (17): : 957 - 957
  • [16] Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia
    Magi, L.
    Marasco, M.
    Rogges, E.
    Dell'Unto, E.
    Rinzivillo, M.
    Pilozzi, E.
    Annibale, B.
    Panzuto, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S957 - S957
  • [17] Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia
    Matteo Marasco
    Ludovica Magi
    Evelina Rogges
    Elisabetta Dell’Unto
    Maria Rinzivillo
    Emanuela Pilozzi
    Bruno Annibale
    Francesco Panzuto
    Endocrine, 2023, 82 : 435 - 441
  • [18] Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors : the end of a story ?
    Delaunoit, T.
    Van den Eynde, M.
    Borbath, I.
    Demetter, P.
    Demolin, G.
    Pattyn, P.
    Pauwels, S.
    Peeters, M.
    Roeyen, G.
    Van Cutsem, E.
    Van Hootegem, Ph.
    Van Laethem, J. L.
    Verslype, C.
    Hendlisz, A.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2009, 72 (01): : 49 - 53
  • [19] Classifications of gastro-entero-pancreatic neuroendocrine tumors: what has changed?
    Scoazec, J-Y
    ONCOLOGIE, 2019, 21 (5-12) : 119 - 124
  • [20] Neuroendocrine tumours of the gastro-entero-pancreatic system:: diagnosis and surgical treatment
    Schürmann, G
    Brüwer, M
    Senniger, N
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2000, 125 (15) : 461 - 464